Mutagenesis vol. 9 no. 4 pp. 367-375, 1994
© 1994 UK Environmental Mutagen Society/Oxford University Press
research-article |
A preliminary evaluation of the performance of the MutaTM Mouse (lacZ) and Big BlueTM (lacl) transgenic mouse mutation assays
Zeneca Central Toxicology Laboratory Alderley Park, Nr Macclesfield, Cheshire SK10 4TJ, UK
All of the published mutagenicity data generated using the MutaTM Mouse (lacZ) and the Big BlueTM (lacl) transgenic mouse mutation assays have been re-presented in a standard format. To date, 26 chemicals have been evaluated in one or other of the assays, and eight tissues have been sampled. The present analysis should expedite the further validation of these assays. In particular, it is suggested that data on the present 26 chemicals should be consolidated rather than the generation of partial data sets on additional chemicals.
1To whom correspondence should be addressed
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Murphey, Y. Yamazaki, C. A. McMahan, C. A. Walter, R. Yanagimachi, and J. R. McCarrey Epigenetic regulation of genetic integrity is reprogrammed during cloning PNAS, March 24, 2009; 106(12): 4731 - 4735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Quillardet, X. Arrault, V. Michel, and E. Touati Organ-targeted mutagenicity of nitrofurantoin in Big Blue transgenic mice Mutagenesis, September 1, 2006; 21(5): 305 - 311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Arrault, V. Michel, P. Quillardet, M. Hofnung, and E. Touati Comparison of kinetics of induction of DNA adducts and gene mutations by a nitrofuran compound, 7-methoxy-2-nitronaphtho[2,1-b]furan (R7000), in the caecum and small intestine of Big BlueTM mice Mutagenesis, July 1, 2002; 17(4): 353 - 359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Eastin, J. H. Mennear, R. W. Tennant, R. E. Stoll, D. G. Branstetter, J. R. Bucher, B. Mccullough, R. L. Binder, J. W. Spalding, and J. F. Mahler Tg.AC Genetically Altered Mouse: Assay Working Group Overview of Available Data Toxicol Pathol, January 1, 2001; 29(1_suppl): 60 - 80. [Abstract] [PDF]
|
|
|
|
|
|
R. Davies, B. Clothier, and A. G. Smith Mutation frequency in the lacI gene of liver DNA from lambda/lacI transgenic mice following the interaction of PCBs with iron causing hepatic cancer and porphyria Mutagenesis, September 1, 2000; 15(5): 379 - 383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Heddle On clonal expansion and its effects on mutant frequencies, mutation spectra and statistics for somatic mutations in vivo Mutagenesis, May 1, 1999; 14(3): 257 - 260. [Full Text] [PDF]
|
|
|
|
|
|
D. G. Rudmann and S. K. Durham Utilization of Genetically Altered Animals in the Pharmaceutical Industry Toxicol Pathol, January 1, 1999; 27(1): 111 - 114. [Abstract] [PDF]
|
|
|
|
|
|
S.W. Dean, T.M. Brooks, B. Burlinson, J. Mirsalis, B. Myhr, L. Recio, and V. Thybaud Transgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing in vivo for the detection of site-of-contact mutagens Mutagenesis, January 1, 1999; 14(1): 141 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. H. Schiestl, J. Aubrecht, F. Khogali, and N. Carls Carcinogens induce reversion of the mouse pink-eyed unstable mutation PNAS, April 29, 1997; 94(9): 4576 - 4581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ashby Alternatives to the 2-species bioassay for the identification of potential human carcinogens Human and Experimental Toxicology, March 1, 1996; 15(3): 183 - 202. [Abstract] [PDF]
|
|